PATENT CLAIM ANALYSIS

Application Number: 15987941
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["514", "380000"]

Abstract:
Described herein are compositions, including an oral dosage regimen, for the treatment of NMDAR-related neuropsychiatric disorders such as depression and obsessive-compulsive disorder and that includes an NMDAR antagonist, such as D-cycloserine formulated to produce plasma levels in excess of 25 microgram/mL, combined with more recently developed antidepressants.

Claim (Index 14):
The method of  claim 1 , wherein the first and second agents are provided in a single pharmaceutical composition.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 93.0
- Lexical Diversity: 1.18182
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15987932', '15650912', '14844021', '13982460', '13936198']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8139872255911987
- 35 USC 102 Novelty (BERT): 0.557429494735132
- Combined Prediction Score: 0.7883314525055921
- Mean Citation Score: 379.61353
- Max Citation Score: 446.9474
- Similarity Product: 292.60880866255764

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test